Drug balloon and preparation method thereof
By forming a binding layer of needle-like and granular crystalline paclitaxel on the surface of the drug balloon, the problem of easy drug fall off during spraying the drug balloon is solved, the firmness and release rate of the drug are improved, and the loss during delivery is reduced Rate.
Patent Information
- Application Number
- CN202410930182.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-12
AI Technical Summary
The existing drug balloons are prone to falling off during spraying, resulting in a high loss rate, and commonly used excipients may cause adverse irritation and allergic reactions.
The combination of needle-like crystalline and granular crystalline paclitaxel is used to form the bottom layer and the surface layer. By regulating the spraying parameters and solution components, the drug forms a firm crystalline state on the surface of the balloon, avoid direct exposure, and reduce the delivery process. loss rate.
It improves the firmness and release rate of the drug balloon, reduces the loss of the drug in the blood vessel, and ensures the effective release of the drug at the lesion position.
Smart Images

Figure CN118925031A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of drug balloons, and in particular to a drug balloon and a preparation method thereof. Background Art
[0002] In the process of stenting for coronary heart disease, balloons are indispensable tools. The main difference between drug-eluting balloons and ordinary balloons is that drugs are coated on the balloon surface. In existing drug-eluting balloon technology, paclitaxel or rapamycin and its drug-loaded matrix are attached to the balloon surface through a spraying process and then delivered to the stenotic lesion. During the process of drug-eluting balloons entering blood vessels for delivery, deployment, expansion, and withdrawal, the drugs are washed away by the blood flow, and very little drugs are released to the lesion site.
[0003] In the preparation of existing drug balloons, the balloon is pressurized and then sprayed during the drug spraying process. However, after the sprayed balloon is folded, the exposed drug is easily lost. In order to reduce drug loss, excipients such as iopromide, urea, natural lac resin, tri-n-hexyl butyryl citrate, etc. are added to the drug used for spraying. By adding excipients, the drug is adhered to the outer surface of the balloon. However, excipients such as iopromide are prone to cause adverse stimulation, allergic inflammation, etc.
[0004] In view of this, the present invention is proposed. Summary of the invention
[0005] One object of the present invention is to provide a drug balloon, which ensures that the drug coating has excellent firmness and good release rate without adding additional excipients.
[0006] Another object of the present invention is to provide a method for preparing the drug balloon.
[0007] In order to achieve the above-mentioned object of the present invention, the present invention provides a drug balloon on one hand, comprising a balloon, wherein a bottom layer and a surface layer are formed on the surface of the balloon;
[0008] The bottom layer includes paclitaxel attached to the balloon surface in a needle-like crystal state; the surface layer includes paclitaxel attached to the bottom layer surface in a granular crystal state, and the surface layer is distributed on the bottom layer surface in a film-like form; the size of the paclitaxel in the needle-like crystal state is larger than the size of the paclitaxel in the granular crystal state.
[0009] In a specific embodiment of the present invention, in the bottom layer, the average length of the long axis of the needle-shaped crystalline paclitaxel is 4 to 8 μm.
[0010] In a specific embodiment of the present invention, in the surface layer, the grain size of the granular crystalline paclitaxel is 0.3-0.5 μm.
[0011] In a specific embodiment of the present invention, the thickness of the bottom layer is 2-8 μm.
[0012] In a specific embodiment of the present invention, the thickness of the surface layer is 0.5-2 μm.
[0013] Another aspect of the present invention provides a method for preparing any one of the above-mentioned drug balloons, comprising the following steps: spraying a first solution on the surface of the balloon to prepare a bottom layer, and then spraying a second solution on the surface of the bottom layer to prepare a surface layer;
[0014] The first solution comprises paclitaxel and an organic solvent, wherein the mass fraction of paclitaxel is 1.4% to 1.8%; the second solution comprises paclitaxel and an organic solvent, wherein the mass fraction of paclitaxel is 1.2% to 1.6%;
[0015] In the spraying of the first solution, the pump flow rate is 60 to 80 μL / min; in the spraying of the second solution, the pump flow rate is 20 to 30 μL / min.
[0016] In a specific embodiment of the present invention, the organic solvent includes at least one of methanol, acetonitrile, ethanol and chloroform.
[0017] In a specific embodiment of the present invention, in the spraying of the first solution, the feed speed is 1.5-1.9 mm / s, the rotation speed is 150-200 rpm. Further, in the spraying of the first solution, the number of spraying is 1-3 times; the spraying height is 10-20 mm; and the drying time is 230-250 s.
[0018] In a specific embodiment of the present invention, in the spraying of the second solution, the feed speed is 1.5-1.9 mm / s, the rotation speed is 150-200 rpm. Further, in the spraying of the second solution, the number of spraying is 3-5 times; the spraying height is 20-30 mm; and the drying time is 90-110 s.
[0019] In a specific embodiment of the present invention, the balloon is subjected to a petal splitting process, and then the balloon is kept under a negative pressure state for the spraying.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] (1) The present invention provides a bottom layer and a surface layer on the balloon surface. The bottom layer uses relatively large needle-shaped crystalline paclitaxel, and the surface layer uses relatively small granular crystalline paclitaxel, which is covered on the needle-shaped crystalline paclitaxel in the bottom layer in a film-like form. On the one hand, the firmness can be improved, and on the other hand, the needle-shaped crystalline paclitaxel is prevented from being directly exposed, thereby reducing the loss rate during intravascular delivery and ensuring the release rate.
[0022] (2) The method for preparing the drug balloon of the present invention can obtain a bottom layer and a surface layer whose crystal state meets the requirements by further adjusting the spraying parameters, and can also ensure that the crystal state of the bottom layer and the surface layer is more uniform. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0024] Figure 1 A schematic diagram of the cross-sectional structure of the drug balloon provided by an embodiment of the present invention under negative pressure after petal separation;
[0025] Figure 2 A schematic diagram of the structure of the balloon under negative pressure after petal separation provided by an embodiment of the present invention;
[0026] Figure 3 A schematic diagram of the structure of another balloon under negative pressure after petal separation provided by an embodiment of the present invention;
[0027] Figure 4 The SEM images of the surface of the drug balloon provided in Example 1 of the present invention; wherein (a) is the SEM image corresponding to the surface layer after spraying, and (b) is the SEM image corresponding to the bottom layer after spraying;
[0028] Figure 5 This is a SEM image of the surface of the drug balloon provided in Example 1 of the present invention (after spraying the surface layer) at another magnification;
[0029] Figure 6 This is a SEM image of the drug balloon provided in Example 1 of the present invention after spraying the bottom layer; wherein (a) is a stereoscopic image of the needle-shaped crystal state of the bottom layer, and (b) is a size image of the needle-shaped crystal state of the bottom layer;
[0030] Figure 7 This is a SEM image of the surface of the drug balloon provided in Comparative Example 1 of the present invention (after spraying the surface layer);
[0031] Figure 8 This is a SEM image of the surface of the drug balloon provided in Comparative Example 5 of the present invention;
[0032] Fig. 9 This is a SEM image of the surface of the drug balloon provided in Comparative Example 4 of the present invention. DETAILED DESCRIPTION
[0033] The technical scheme of the present invention will be clearly and completely described below in conjunction with the accompanying drawings and specific embodiments, but it will be understood by those skilled in the art that the following described embodiments are part of embodiments of the present invention, rather than all embodiments, and are only used to illustrate the present invention, and should not be considered as limiting the scope of the present invention. Based on the embodiments in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work are within the scope of protection of the present invention. If specific conditions are not specified in the embodiments, they are carried out according to normal conditions or conditions recommended by the manufacturer. If the manufacturer is not specified in the reagents or instruments used, they are all conventional products that can be purchased commercially.
[0034] On the one hand, the present invention provides a drug balloon, such as Figure 1 As shown, Figure 1 A schematic diagram of the cross-sectional structure of the drug balloon provided in an embodiment of the present invention under negative pressure after petal separation, wherein Figure 1 (b) in Figure 1 The partial enlarged view of (a) in the figure. The drug balloon of this embodiment includes a balloon, and a bottom layer and a surface layer are formed on the surface of the balloon. The bottom layer includes paclitaxel attached to the surface of the balloon in a needle-like crystal state; the surface layer includes paclitaxel attached to the surface of the bottom layer in a granular crystal state, and the surface layer is distributed in a film-like form on the surface of the bottom layer; the size of the paclitaxel in the needle-like crystal state is larger than the size of the paclitaxel in the granular crystal state.
[0035] The present invention arranges a bottom layer and a surface layer on the surface of the balloon. The bottom layer adopts relatively large needle-shaped crystalline paclitaxel, and the surface layer adopts relatively small granular crystalline paclitaxel, which is covered on the needle-shaped crystalline paclitaxel of the bottom layer in a film-like form. On the one hand, the firmness can be improved, and on the other hand, the needle-shaped crystalline paclitaxel is prevented from being directly exposed, thereby reducing the loss rate of transportation in the blood vessel and ensuring the release rate.
[0036] In a specific embodiment of the present invention, in the bottom layer, the average long axis size of the needle-shaped crystalline paclitaxel is 4 to 8 μm, and the average short axis size is about 0.1 to 2.5 μm, but not limited thereto.
[0037] For example, in different embodiments, in the bottom layer, the average length of the long axis of the needle-shaped crystalline paclitaxel may be 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, or a range consisting of any two thereof.
[0038] Among them, the bottom layer is in a needle-shaped crystal state. If the crystal size is too large, large particles are easily shed under blood flushing, resulting in the risk of terminal thrombosis caused by excessive particles; if the crystal size is too small, the firmness is poor, and a large degree of drug loss occurs before reaching the lesion. The present invention regulates the size of the needle-shaped paclitaxel in the bottom layer within the above range, further taking into account the firmness to reduce drug loss and ensure safety.
[0039] In a specific embodiment of the present invention, in the surface layer, the grain size of the granular crystalline paclitaxel is 0.3-0.5 μm.
[0040] For example, in different embodiments, in the surface layer, the grain size of the granular crystalline paclitaxel may be 0.3 μm, 0.35 μm, 0.4 μm, 0.45 μm, 0.5 μm, or a range consisting of any two of them.
[0041] The surface layer of the present invention covers the surface of the needle-shaped crystals of the bottom layer in the form of a film, and the size of the appropriate granular crystals is regulated so that the film-like surface layer is lost in the blood under blood flushing, ensuring that as many needle-shaped crystals as possible are released at the lesion site.
[0042] In a specific embodiment of the present invention, the thickness of the bottom layer is 2-8 μm, and the thickness of the surface layer is 0.5-2 μm.
[0043] For example, in different embodiments, the thickness of the bottom layer can be 2μm, 2.5μm, 3μm, 3.5μm, 4μm, 4.5μm, 5μm, 5.5μm, 6μm, 6.5μm, 7μm, 7.5μm, 8μm or any two thereof, and the thickness of the surface layer can be 0.5μm, 1μm, 1.5μm, 2μm or any two thereof. By regulating the thickness of the bottom layer and the surface layer within the above range, the bottom layer needle-shaped crystalline drug has a good drying crystallization state after spraying, and the drug has high firmness; a part of the granular surface layer is washed by the blood flow during the balloon delivery process, and a part of it fully protects the bottom layer needle-shaped drug crystals, so that the drug of the drug balloon is released to the lesion site to the greatest extent.
[0044] Another aspect of the present invention provides a method for preparing any of the above-mentioned drug balloons, comprising the following steps: spraying a first solution on the surface of the balloon to prepare a bottom layer, and then spraying a second solution on the surface of the bottom layer to prepare a surface layer;
[0045] The first solution includes paclitaxel and an organic solvent, and the mass fraction of paclitaxel is 1.4% to 1.8%; the second solution includes paclitaxel and an organic solvent, and the mass fraction of paclitaxel is 1.2% to 1.6%;
[0046] When spraying the first solution, the pump flow rate is 60 to 80 μL / min; when spraying the second solution, the pump flow rate is 20 to 30 μL / min.
[0047] In the preparation of the drug balloon of the present invention, the solution used for spraying does not include excipients (such as iopromide, urea, eugenol, etc.), but only includes the active drug paclitaxel and an organic solvent. The organic solvent evaporates during the drying process of spraying, so that paclitaxel is retained on the outer surface of the balloon in a certain crystalline state.
[0048] The present invention coordinates and controls the spraying flow rate and the mass fraction of paclitaxel in the spraying solution, utilizes the volatilization of the organic solvent in the drying process of spraying, and makes the paclitaxel of the bottom layer and the surface layer precipitate in situ in different crystal states to form on the outer surface of the balloon, which can significantly improve the bonding firmness between the bottom layer paclitaxel and the balloon surface, and between the surface layer paclitaxel and the bottom layer paclitaxel. Compared with other methods that control the ratio of solvent and poor solvent to make the paclitaxel in the spraying solution exist in the form of aggregates with a certain size at the microscopic level, and then spray, the bonding strength between the paclitaxel aggregates is insufficient, which easily causes the drug to fall off and the loss rate increases.
[0049] For example, in different embodiments, in the first solution, the mass fraction of paclitaxel can be 1.4%, 1.5%, 1.6%, 1.7%, 1.8% or a range consisting of any two thereof; in the second solution, the mass fraction of paclitaxel can be 1.2%, 1.3%, 1.4%, 1.5%, 1.6% or a range consisting of any two thereof. By regulating the mass fraction of paclitaxel in the first solution and the second solution within the above range, the corresponding bottom layer and surface layer are formed in coordination with the remaining process parameters. Among them, the mass fraction of the first solution is high, the proportion of organic solvent is low, and the remaining drug forms needle-shaped crystals of the bottom layer after the organic solution evaporates. The organic solvent evaporates for a short time during the spraying and rotating drying process, the remaining drug crystallization time is long, the drug concentration is high, and needles are formed; the mass fraction of the second solution is low, the proportion of organic solvent is high, the volatilization time is long during its spraying and rotating drying process, the corresponding drug crystallization time is shortened, and small particles of film-like crystals are formed to cover evenly.
[0050] For example, in different embodiments, when spraying the first solution, the pump flow rate can be 60 μL / min, 65 μL / min, 70 μL / min, 75 μL / min, 80 μL / min, or a range consisting of any two thereof; when spraying the second solution, the pump flow rate can be 20 μL / min, 22 μL / min, 25 μL / min, 28 μL / min, 30 μL / min, or a range consisting of any two thereof. By regulating the pump flow rates when spraying the first solution and the second solution within the above range, the particle size of the crystals is controlled within a relatively small range while ensuring uniformity.
[0051] In a specific embodiment of the present invention, the organic solvent includes at least one of methanol, acetonitrile, ethanol and chloroform.
[0052] In a specific embodiment of the present invention, in spraying the first solution, the feed speed is 1.5-1.9 mm / s, the rotation speed is 150-200 rpm. Further, in spraying the first solution, the number of spraying is 1-3 times; the spraying height is 10-30 mm; and the drying time is 230-250 s.
[0053] For example, in different embodiments, in the first solution of spraying, the feed rate can be 1.5mm / s, 1.6mm / s, 1.7mm / s, 1.8mm / s, 1.9mm / s or any two of them; the rotation speed can be 150rpm, 160rpm, 170rpm, 180rpm, 190rpm, 200rpm or any two of them; the number of spraying times can be 1 time, 2 times or 3 times, preferably 2 times; the spraying height (the distance from the nozzle to the spraying surface) can be 10mm, 15mm, 20mm, 25mm, 30mm or any two of them; the drying time can be 230s, 235s, 240s, 245s, 250s or any two of them. By regulating and controlling each spraying parameter (such as pump flow, feed rate, number of spraying times, spraying height and drying time) within the above range, on the one hand, it is ensured that the corresponding bottom layer forms a certain form of crystalline state, on the other hand, the spraying process is more stable, and the drying time is shortened to a certain extent, and the spraying efficiency is improved.
[0054] In a specific embodiment of the present invention, when spraying the second solution, the feed speed is 1.5-1.9 mm / s, the rotation speed is 150-200 rpm. Further, when spraying the second solution, the number of spraying is 3-5 times; the spraying height is 20-30 mm; and the drying time is 90-110 s.
[0055] For example, in different embodiments, when spraying the second solution, the feed rate can be 1.5mm / s, 1.6mm / s, 1.7mm / s, 1.8mm / s, 1.9mm / s or any two of them; the rotation speed can be 150rpm, 160rpm, 170rpm, 180rpm, 190rpm, 200rpm or any two of them; the number of spraying times can be 3 times, 4 times or 5 times, preferably 4 times; the spraying height (the distance from the nozzle to the spraying surface) can be 20mm, 22mm, 25mm, 28mm, 30mm or any two of them; the drying time can be 90s, 95s, 100s, 105s, 110s or any two of them. By regulating each spraying parameter (such as pump flow, feed rate, number of spraying times, spraying height and drying time) within the above range, on the one hand, it is ensured that the corresponding surface layer forms a certain form of crystalline state, and on the other hand, the spraying process is more stable.
[0056] In a specific embodiment of the present invention, the balloon is split into petals, and then the balloon is kept under negative pressure for spraying. By splitting the petals first and then folding them, the active ingredient paclitaxel is locked inside the balloon, reducing the effective drug exposed to the outside, allowing the drug to fully reach the lesion site and be released, thereby improving the bioavailability of the effective drug paclitaxel.
[0057] Figure 2 and Figure 3 They are two structural schematic diagrams of the balloon under negative pressure after being split according to the embodiments of the present invention. Specifically, the balloon is split by a folding machine, and after splitting, a needleless connector is used to keep the balloon in a negative pressure state, and the balloon is installed on a sprayer for spraying. When spraying, you can choose to connect the distal semi-finished balloon to the conversion connector, and then connect the needleless connector, and maintain the component in a negative pressure state without leakage for spraying. You can also choose to connect the catheter seat of the complete product to the needleless connector to maintain a negative pressure state for spraying.
[0058] Example 1
[0059] This embodiment provides a method for preparing a drug balloon, comprising the following steps:
[0060] (1) Using methanol as a solvent, a paclitaxel solution with a mass fraction of 1.6% was prepared as a first solution, and a paclitaxel solution with a mass fraction of 1.4% was prepared as a second solution.
[0061] (2) The balloon is split into petals by a folding machine, a needleless connector is used to keep the balloon in a negative pressure state, and the balloon is installed on a spraying machine for spraying to obtain a drug balloon, which is folded after spraying. The spraying operation includes: first spraying the first solution on the balloon surface, the pump flow is 70 μL / min, the feed speed is 1.7 mm / s, the rotation speed is 180 rpm, the number of sprays is 2 times, the spray height is 15 mm, and the drying time is 240 s; then spraying the second solution on the balloon surface formed with the bottom layer, the pump flow is 25 μL / min, the feed speed is 1.7 mm / s, the rotation speed is 180 rpm, the number of sprays is 4 times, the spray height is 25 mm, and the drying time is 100 s.
[0062] Example 2
[0063] This embodiment provides a method for preparing a drug balloon, referring to Example 1, with the only difference being that when spraying the bottom layer, the spraying conditions are different.
[0064] The conditions for spraying the bottom layer include: first spraying the first solution on the balloon surface, the pump flow rate is 80 μL / min, the feed speed is 1.9 mm / s, the rotation speed is 200 rpm, the number of spraying is 2 times, the spraying height is 15 mm, and the drying time is 240 s.
[0065] Example 3
[0066] This embodiment provides a method for preparing a drug balloon, referring to Example 1, with the only difference being that when spraying the bottom layer, the spraying conditions are different.
[0067] The conditions for spraying the bottom layer include: first spraying the first solution on the balloon surface, the pump flow rate is 60 μL / min, the feed speed is 1.5 mm / s, the rotation speed is 150 rpm, the number of spraying times is 2 times, the spraying height is 15 mm, and the drying time is 240 s.
[0068] Example 4
[0069] This embodiment provides a method for preparing a drug balloon, referring to Example 1, with the only difference being that when spraying the surface layer, the spraying conditions are different.
[0070] The conditions for spraying the surface layer include: spraying the second solution on the balloon surface, a pump flow of 20 μL / min, a feed speed of 1.5 mm / s, a rotation speed of 150 rpm, four spray times, a spray height of 25 mm, and a drying time of 100 s.
[0071] Example 5
[0072] This embodiment provides a method for preparing a drug balloon, referring to Example 1, with the only difference being that when spraying the surface layer, the spraying conditions are different.
[0073] The conditions for spraying the surface layer include: spraying the second solution on the balloon surface, a pump flow of 30 μL / min, a feed speed of 1.9 mm / s, a rotation speed of 200 rpm, four spray times, a spray height of 25 mm, and a drying time of 100 s.
[0074] Comparative Example 1
[0075] Comparative Example 1 provides a method for preparing a drug balloon, referring to Example 1, except that the spraying conditions are different.
[0076] The conditions for spraying the bottom layer include: first spraying the first solution on the balloon surface, the pump flow rate is 90 μL / min, the feed speed is 1.2 mm / s, the number of spraying is 2 times, the spraying height is 15 mm, and the drying time is 300 s.
[0077] The conditions for spraying the surface layer include: first spraying the second solution on the balloon surface, the pump flow rate is 40 μL / min, the feed speed is 1.2 mm / s, the number of spraying is 4 times, the spraying height is 25 mm, and the drying time is 100 s.
[0078] Comparative Example 2
[0079] Comparative Example 2 provides a method for preparing a drug balloon, referring to Example 1, except that only the bottom layer is sprayed, and no surface layer is further sprayed on the surface of the bottom layer.
[0080] The conditions for spraying the bottom layer include spraying the first solution on the balloon surface first, a pump flow of 70 μL / min, a feed speed of 1.7 mm / s, a rotation speed of 180 rpm, two spray times, a spray height of 15 mm, and a drying time of 240 s.
[0081] Comparative Example 3
[0082] Comparative Example 3 provides a method for preparing a drug balloon, referring to Example 1, except that the surface layer is sprayed directly on the balloon surface without spraying the bottom layer.
[0083] The conditions for spraying the bottom layer include: spraying the second solution on the balloon surface formed with the bottom layer, the pump flow rate is 25 μL / min, the feed speed is 1.7 mm / s, the rotation speed is 180 rpm, the number of spraying times is 4 times, the spraying height is 25 mm, and the drying time is 100 s.
[0084] Comparative Example 4
[0085] Comparative Example 4 provides a method for preparing a drug balloon, referring to Example 1, except that the spraying conditions are different when spraying the bottom layer.
[0086] The conditions for spraying the bottom layer include: first spraying the first solution on the balloon surface, the pump flow rate is 90 μL / min, the feed speed is 1.5 mm / s, the number of spraying is 2 times, the spraying height is 15 mm, and the drying time is 240 s.
[0087] Comparative Example 5
[0088] Comparative Example 5 provides a method for preparing a drug balloon, referring to Example 1, with the only difference being that when spraying the surface layer, the spraying conditions are different.
[0089] The conditions for spraying the surface layer include: spraying the second solution on the balloon surface, a pump flow rate of 40 μL / min, a feed speed of 1.7 mm / s, a spraying number of 4 times, a spraying height of 25 mm, and a drying time of 100 s.
[0090] Comparative Example 6
[0091] Comparative Example 6 provides a method for preparing a drug balloon, referring to Example 1, with the only difference being that the spraying operation is different.
[0092] In Comparative Example 6, the spraying operation includes: first spraying the second solution on the balloon surface, with a pump flow of 25 μL / min, a feed speed of 1.7 mm / s, a rotation speed of 180 rpm, four spraying times, a spraying height of 25 mm, and a drying time of 100 s; then spraying the first solution, with a pump flow of 70 μL / min, a feed speed of 1.7 mm / s, two spraying times, a spraying height of 15 mm, and a drying time of 240 s.
[0093] Experimental Example 1
[0094] Figures 4 to 9 The SEM images of the surfaces of the drug balloons provided in the embodiments of the present invention and the comparative examples are shown respectively.
[0095] The crystal morphology, size, thickness, etc. of the bottom layer and the surface layer of different embodiments and comparative examples were further characterized. The results are shown in Table 1.
[0096] Table 1 Test results of different embodiments and comparative examples
[0097]
[0098] Experimental Example 2
[0099] The loss rate and release rate of the drug balloons of different embodiments and comparative examples were tested, and the test results are shown in Table 2 and Table 3, respectively.
[0100] Among them, the test methods of loss rate include:
[0101] (1) Prepare normal saline (0.9% sodium chloride solution).
[0102] (2) Place the medium-difficulty coronary artery model with a Y-type hemostatic valve, a guide catheter, and a guide wire into a sufficiently large water bath, inject the prepared saline solution into the water bath, and make sure that the liquid level at least covers the coronary artery model. Adjust the water bath temperature to 37°C.
[0103] (3) After the temperature of the water bath stabilizes at 37°C, connect the pressure device or a syringe with a Luer connector to the side port of the Y-type hemostatic valve, tighten the hemostatic valve at the guide wire port, and use the pressure device or a syringe with a Luer connector to pump back and forth to completely expel the air inside the guide catheter and fill it with saline.
[0104] (4) Carefully remove the protective cover of the prepared coronary drug-coated balloon dilatation catheter, place the balloon dilatation catheter along the guide wire at the hemostatic valve port, open the hemostatic valve, and quickly insert the sample along the guide wire. After the sample reaches the tip of the guide catheter and the balloon is fully exposed, immediately withdraw it. The total time for entry and withdrawal is 15 to 20 seconds. After the sample catheter is completely withdrawn, test the paclitaxel content on the sample and record the data.
[0105] (5) Calculation
[0106] The theoretical content of paclitaxel is set as X1;
[0107] The measured paclitaxel content was set as X2;
[0108] The loss rate after passing through the guide catheter is:
[0109] [(X1-X2) / X1]×100%
[0110] Release rate test methods include:
[0111] (1) Prepare normal saline (0.9% sodium chloride solution).
[0112] (2) Place the medium-difficulty coronary artery model with a Y-type hemostatic valve, a guide catheter, and a guide wire into a sufficiently large water bath, inject the prepared saline solution into the water bath, and make sure that the liquid level at least covers the coronary artery model. Adjust the water bath temperature to 37°C.
[0113] (3) After the temperature of the water bath stabilizes at 37°C, connect the pressure device or a syringe with a Luer connector to the side port of the Y-type hemostatic valve, tighten the hemostatic valve at the guide wire port, and use the pressure device or a syringe with a Luer connector to pump back and forth to completely expel the air inside the guide catheter and fill it with saline.
[0114] (4) Carefully remove the protective cover of the prepared coronary drug-coated balloon dilatation catheter, place the balloon dilatation catheter along the guide wire at the hemostatic valve port, open the hemostatic valve, and quickly insert the sample along the guide wire. The sample entry time should be kept within 30 seconds. When the sample is completely exposed through the guide catheter, the coronary artery model, and the balloon, remove the balloon and the coronary artery model from the water bath, and use a pressurizing device to open the sample balloon with purified water at 6 atm.
[0115] (5) A 50 mL beaker was fixed in a shaking device, the temperature was set to 37 ± 0.5 °C, the shaking speed was set to 100 rpm, a 50 mL beaker containing 40 mL PBS-T (pH = 7.4, Tween 20 content of 0.05 wt%) was fixed in the shaking device, the device was turned on, and the shaking device was kept shaking steadily.
[0116] (6) Holding the coronary artery model, completely immerse the opened sample balloon catheter in PBS-T and start timing. After 3 minutes of release, remove the sample balloon.
[0117] (7) Place the sample balloon and the coronary artery model back into the water bath, and use the inflation device connected to the sample balloon to start suctioning the balloon with negative pressure. When the sample balloon is completely deflated, quickly withdraw the sample balloon, and keep the withdrawal time at about 30 seconds. Pick up the balloon catheter, and carefully absorb the liquid on the balloon surface with filter paper. Measure the paclitaxel content of the sample and record the data.
[0118] (8) Calculation
[0119] The theoretical content of paclitaxel is set as X1;
[0120] The determined paclitaxel content is set as X3,
[0121] The release rate is:
[0122] [(X1-X3) / X1]×100%
[0123] The release rate at the lesion location is: release rate - loss rate.
[0124] When conducting the loss rate and release rate tests, samples of 5 specifications of drug balloons were taken for testing respectively, using the same test method and the same operation time.
[0125] Table 2 Loss rate test results of different embodiments and comparative examples
[0126]
[0127]
[0128]
[0129] Table 3 Test results of release rate and lesion position release rate of different embodiments and comparative examples
[0130]
[0131]
[0132]
[0133] The drug balloon has high firmness, and the drug loss rate during balloon delivery in PCI surgery will be reduced, and the drug release rate is stable and efficient; combining the two dimensions of loss rate and release rate, it can be seen from the above test results that: the loss rate of the drug balloon of the present invention is significantly reduced, indicating that the firmness of the drug balloon of the present invention is significantly improved. And the release rate of the drug balloon of the present invention is stable at 80% ± 15% as per the acceptance standard, which meets the requirements for the use of drug balloons. And the release rate values of drug balloons of different specifications are comparable, the product is relatively stable, and the morphological properties of the drug will not change with changes in balloon specifications.
[0134] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A drug balloon, characterized in that: The invention comprises a balloon, wherein the surface of the balloon is formed with a bottom layer and a surface layer; The bottom layer includes paclitaxel attached to the balloon surface in a needle-like crystal state; the surface layer includes paclitaxel attached to the bottom layer surface in a granular crystal state, and the surface layer is distributed on the bottom layer surface in a film-like form; the size of the paclitaxel in the needle-like crystal state is larger than the size of the paclitaxel in the granular crystal state.
2. The drug balloon according to claim 1, characterized in that: In the bottom layer, the average length of the long axis of the needle-shaped crystalline paclitaxel is 4 to 8 μm.
3. The drug balloon according to claim 1, characterized in that: In the surface layer, the grain size of the granular crystalline paclitaxel is 0.3-0.5 μm.
4. The drug balloon according to claim 1, characterized in that: The thickness of the bottom layer is 2-8 μm.
5. The drug balloon according to claim 1, characterized in that: The thickness of the surface layer is 0.5-2 μm.
6. The method for preparing the drug balloon according to any one of claims 1 to 5, characterized in that: The method comprises the following steps: spraying a first solution on the surface of the balloon to prepare a bottom layer, and then spraying a second solution on the surface of the bottom layer to prepare a surface layer; The first solution comprises paclitaxel and an organic solvent, wherein the mass fraction of paclitaxel is 1.4% to 1.8%; the second solution comprises paclitaxel and an organic solvent, wherein the mass fraction of paclitaxel is 1.2% to 1.6%; In the spraying of the first solution, the pump flow rate is 60 to 80 μL / min; in the spraying of the second solution, the pump flow rate is 20 to 30 μL / min.
7. The method for preparing the drug balloon according to claim 6, characterized in that: The organic solvent includes at least one of methanol, acetonitrile, ethanol and chloroform.
8. The method for preparing the drug balloon according to claim 6, characterized in that: In the spraying of the first solution, the feed speed is 1.5 to 1.9 mm / s and the rotation speed is 150 to 200 rpm; Preferably, in the spraying of the first solution, the number of spraying is 1 to 3 times; the spraying height is 10 to 30 mm; and the drying time is 230 to 250 seconds.
9. The method for preparing the drug balloon according to claim 6, characterized in that: In the spraying of the second solution, the feed speed is 1.5 to 1.9 mm / s and the rotation speed is 150 to 200 rpm; Preferably, in the spraying of the second solution, the number of spraying is 3 to 5 times; the spraying height is 20 to 30 mm; and the drying time is 90 to 110 seconds.
10. The method for preparing the drug balloon according to claim 6, characterized in that: The balloon is split into petals, and then the balloon is kept under negative pressure to perform the spraying.
